CS136191A3 - Pharmaceutical - Google Patents

Pharmaceutical Download PDF

Info

Publication number
CS136191A3
CS136191A3 CS911361A CS136191A CS136191A3 CS 136191 A3 CS136191 A3 CS 136191A3 CS 911361 A CS911361 A CS 911361A CS 136191 A CS136191 A CS 136191A CS 136191 A3 CS136191 A3 CS 136191A3
Authority
CS
Czechoslovakia
Prior art keywords
biologically active
derivatives
pharmaceutical composition
analogs
administration
Prior art date
Application number
CS911361A
Other languages
Czech (cs)
English (en)
Inventor
Erik Bechgaard
Sveinbjorn Gizurarson
Rolf Kuhlman Hjortkjaer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK117090A external-priority patent/DK117090D0/da
Priority claimed from DK207590A external-priority patent/DK207590D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CS136191A3 publication Critical patent/CS136191A3/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS911361A 1990-05-10 1991-05-08 Pharmaceutical CS136191A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK117090A DK117090D0 (da) 1990-05-10 1990-05-10 Composition for intranasal administration of biol ogically active benzodiazepine compounds
DK207590A DK207590D0 (da) 1990-08-30 1990-08-30 Farmaceutisk praeparat

Publications (1)

Publication Number Publication Date
CS136191A3 true CS136191A3 (en) 1992-04-15

Family

ID=26065326

Family Applications (1)

Application Number Title Priority Date Filing Date
CS911361A CS136191A3 (en) 1990-05-10 1991-05-08 Pharmaceutical

Country Status (14)

Country Link
US (2) US5428006A (zh)
EP (1) EP0532546B1 (zh)
JP (1) JP3219096B2 (zh)
CN (1) CN1056812A (zh)
AT (1) ATE164080T1 (zh)
AU (3) AU7880991A (zh)
CS (1) CS136191A3 (zh)
DE (1) DE69129110T2 (zh)
DK (1) DK0532546T3 (zh)
ES (1) ES2117642T3 (zh)
IE (1) IE911577A1 (zh)
IL (1) IL98089A0 (zh)
PT (1) PT97610A (zh)
WO (1) WO1991016929A1 (zh)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129110T2 (de) * 1990-05-10 1998-12-10 Bechgaard International Research And Development A/S, Hellerup Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
NZ246137A (en) 1991-12-19 1996-04-26 Univ Saskatchewan Mature desiccation tolerant gymnosperm somatic embryos and their production
GB2267435A (en) * 1992-06-01 1993-12-08 British Tech Group Factor VIII
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
EP0621033A1 (en) * 1993-04-20 1994-10-26 Nostras S.A. Antibiotic composition containing oxytetracycline and glycofurol
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
WO1995011042A1 (fr) * 1993-10-21 1995-04-27 Hisamitsu Pharmaceutical Co., Inc. Composition administree par voie nasale et preparation contenant celle-ci
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
HU226562B1 (en) * 1995-02-22 2009-04-28 Novartis Ag 1-aryl-2-acylamino-ethane compounds as neurokinin, especially neurokinin-1 antagonists, and medicaments containing the said compounds.
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6221854B1 (en) * 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US5942499A (en) * 1996-03-05 1999-08-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US5869082A (en) * 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
EP1029536B1 (en) 1997-10-01 2007-11-28 Novadel Pharma Inc. Buccal non-polar spray
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6391282B1 (en) * 1997-11-10 2002-05-21 Flemington Pharmaceutical Corp. Antihistamine sprays and ointments for relief of delayed contact dermatitis
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
AU5397300A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
AU5072000A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for nasally administering water-soluble active substances
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
KR100715513B1 (ko) * 1999-07-26 2007-05-08 에스케이 코오포레이션 경비 항경련성 조성물
FR2796843B1 (fr) * 1999-07-29 2003-05-09 So Ge Val Sa Composition antipyretique concentree et stabilisee a usage veterinaire destine a etre incorporee a l'alimentation des animaux ainsi que procede d'incorporation de cette composition a l'eau de boisson d'animaux
CA2385533C (en) 1999-10-04 2008-03-25 Shearwater Corporation Polymer stabilized neuropeptides
CN1183965C (zh) 2000-02-04 2005-01-12 尤尼金实验室公司 鼻内降钙素制剂
AU772029B2 (en) * 2000-03-08 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
UA77398C2 (en) * 2000-07-31 2006-12-15 Nycomed Danmark As Fentanyl composition for intranasal administration
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
WO2003024425A1 (en) * 2001-09-19 2003-03-27 Elan Pharma International, Ltd. Nanoparticulate insulin formulations
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
AU2002365083A1 (en) * 2001-10-17 2003-06-30 Ganado Research, L.L.C. Composition and method to treat viral bacterial and parasitic infections and infestations
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US6641799B2 (en) 2002-04-03 2003-11-04 Nos Spray, Inc. Nasal spray for decongesting nasal passages
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
BR0305628A (pt) * 2002-07-09 2004-09-08 Palatin Technologies Inc Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
CA2520775A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US8524665B2 (en) * 2003-05-13 2013-09-03 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
CA2529489C (en) * 2003-06-17 2012-01-03 Sk Corporation Transnasal microemulsions containing diazepam
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
EP1794182B1 (en) * 2004-10-01 2015-06-03 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Compounds that modulate trh actions and inhibit the trh-degrading enzyme
CA2596031C (en) * 2005-02-01 2013-02-19 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenic and its pharmaceutically acceptable salts
JP5577021B2 (ja) 2005-02-17 2014-08-20 アボット・ラボラトリーズ 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007115175A2 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
WO2007115182A2 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2015632B1 (en) * 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods
CN101678112B (zh) 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CA2687085A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
WO2009027697A2 (en) * 2007-08-31 2009-03-05 Archimedes Development Limited Non-aqueous pharmaceutical compositions
US8507468B2 (en) 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
WO2009046444A2 (en) * 2007-10-05 2009-04-09 Mdrna, Inc. Formulation for intranasal administration of diazepam
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
CN102458436B (zh) 2009-06-08 2015-06-03 帕拉丁科技公司 黑皮质素受体特异性肽
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト及びメチオニンを含む薬学的組成物
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
SG193389A1 (en) 2011-03-10 2013-10-30 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2917973T3 (es) * 2011-06-14 2022-07-12 Neurelis Inc Administración de benzodiacepina
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013138340A1 (en) 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2957399C (en) 2014-08-06 2023-09-26 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
WO2016044683A1 (en) 2014-09-19 2016-03-24 Tensive Controls, Inc. Anti-microbial peptides
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2018222922A1 (en) 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) * 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
HU190841B (en) * 1983-02-04 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for the production of cyclodextrin polymers swelling in water quickly and to a high extent
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0278997A1 (de) * 1987-02-17 1988-08-24 Siegfried Aktiengesellschaft Azapropazon-Rektalkapseln
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
DE3939492A1 (de) * 1989-11-29 1991-06-06 Mack Chem Pharm Pharmazeutische zubereitungen
DE69129110T2 (de) * 1990-05-10 1998-12-10 Bechgaard International Research And Development A/S, Hellerup Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole

Also Published As

Publication number Publication date
ATE164080T1 (de) 1998-04-15
DE69129110T2 (de) 1998-12-10
AU7880991A (en) 1991-11-27
EP0532546B1 (en) 1998-03-18
AU1358695A (en) 1995-06-01
JPH05507085A (ja) 1993-10-14
US5428006A (en) 1995-06-27
JP3219096B2 (ja) 2001-10-15
DE69129110D1 (de) 1998-04-23
ES2117642T3 (es) 1998-08-16
WO1991016929A1 (en) 1991-11-14
DK0532546T3 (da) 1998-12-28
CN1056812A (zh) 1991-12-11
IE911577A1 (en) 1991-11-20
IL98089A0 (en) 1992-06-21
AU654950B2 (en) 1994-12-01
PT97610A (pt) 1992-01-31
US5693608A (en) 1997-12-02
AU687496B2 (en) 1998-02-26
AU7643591A (en) 1991-11-14
EP0532546A1 (en) 1993-03-24

Similar Documents

Publication Publication Date Title
CS136191A3 (en) Pharmaceutical
US5397771A (en) Pharmaceutical preparation
US10052333B2 (en) Methods and systems for the delivery of a therapeutic agent
JP6295314B2 (ja) 治療薬を送達するための方法および組成物
JP2017155060A5 (zh)
Quadir et al. Development and evaluation of nasal formulations of ketorolac
JP2006501220A (ja) 薬剤の投与及び吸収促進方法
JP3418423B2 (ja) 経粘膜投与用薬剤組成物
CA2082495C (en) A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
Dugger III et al. Immediate-Immediate Release (I2R) Lingual or Buccal Spray Formulations for Transmucosal Delivery of Drug Substances
AU2018202245A1 (en) Methods and compositions for the delivery of a therapeutic agent